ET80 Stock Chart & Stats
€4.81
€0.20(4.34%)
At close: 4:00 PM EDT
€4.81
€0.20(4.34%)
Day’s Range― - ―
52-Week Range€1.49 - €9.72
Previous CloseN/A
Volume0.00
Average Volume (3M)18.00
Market Cap
€4.66M
Enterprise Value-€1.80
Total Cash (Recent Filing)€5.01M
Total Debt (Recent Filing)€2.02M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.42
Shares Outstanding1,061,386
10 Day Avg. Volume55
30 Day Avg. Volume18
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)0.29
P/FCF Ratio-0.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained TTM revenue growth (~6.3%) indicates improving top-line traction versus prior periods. Over 2–6 months this trend can provide runway to scale R&D and commercial efforts, helping narrow losses if management maintains sales execution and controls operating cadence.
Low LeverageVery low debt (debt-to-equity ~0.13) reduces near-term solvency and interest burdens, giving the company financing flexibility. For a cash-burning pharma firm, low leverage lowers bankruptcy risk and preserves optionality for equity, licensing, or strategic transactions over the medium term.
Industry ExposureOperating in Medical - Pharmaceuticals provides structural demand, long product lifecycles, and frequent partnership/licensing opportunities. This sector profile supports durable revenue streams and exit options (licensing/M&A) that can help commercialize assets and offset cash burn over multiple quarters.
Bears Say
Persistent Cash BurnMaterial negative operating and free cash flow (~-$8.7M TTM) is a structural weakness: it depletes reserves and forces external financing or dilution unless operations become cash-generative. Over several months this constrains R&D, commercialization plans and increases dependence on capital markets.
Deep Negative MarginsExtremely negative margins (EBIT/EBITDA ~-109%/-91%, net ~-96%) show the business is far from profitable. Such structural unprofitability implies ongoing losses even with revenue growth, limiting internal funding capacity and making sustainable operations dependent on external capital or major cost structure changes.
Equity Volatility / Financing RiskHistorical volatility in equity levels signals prior financing and potential dilution risk. Coupled with persistent cash burn, this raises a meaningful likelihood of additional equity or transformative financings in the medium term, which can dilute shareholders and alter capital structure.
COSCIENS Biopharma News
ET80 FAQ
What was COSCIENS Biopharma’s price range in the past 12 months?
COSCIENS Biopharma lowest stock price was €1.49 and its highest was €9.72 in the past 12 months.
What is COSCIENS Biopharma’s market cap?
COSCIENS Biopharma’s market cap is €4.66M.
When is COSCIENS Biopharma’s upcoming earnings report date?
COSCIENS Biopharma’s upcoming earnings report date is Aug 13, 2026 which is in 11 days.
How were COSCIENS Biopharma’s earnings last quarter?
COSCIENS Biopharma released its earnings results on May 12, 2026. The company reported -€0.434 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is COSCIENS Biopharma overvalued?
According to Wall Street analysts COSCIENS Biopharma’s price is currently Overvalued.
Does COSCIENS Biopharma pay dividends?
COSCIENS Biopharma does not currently pay dividends.
What is COSCIENS Biopharma’s EPS estimate?
COSCIENS Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSCIENS Biopharma have?
COSCIENS Biopharma has 1,061,386 shares outstanding.
What happened to COSCIENS Biopharma’s price movement after its last earnings report?
COSCIENS Biopharma reported an EPS of -€0.434 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.686%.
Which hedge fund is a major shareholder of COSCIENS Biopharma?
Currently, no hedge funds are holding shares in DE:ET80
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSCIENS Biopharma
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Technical Analysis
BetterLife Pharma
―
PharmaTher Holdings Ltd
―
Glow LifeTech
―
Marvel Biosciences Corp
―
PharmAla Biotech Holdings, Inc.
―